Equinox Ophthalmic Closes Series C Financing

On August 5th, Stradling client Equinox Ophthalmic, Inc. consummated the initial closing of a $22 million Series C Preferred Stock financing. The initial closing of over $13 million included existing investors Visionary Venture FundBluestem Ventures and Stradling client, Flying L Partners

Equinox develops innovative solutions and treatments that promise better management for glaucoma patients through understanding, measuring, and controlling the balance of eye and brain pressures (IOP and ICP). Through dedicated research into the physics of eye pressure, Equinox is developing revolutionary technology designed to restore the balance between IOP and ICP.

The Newport Beach-based deal team representing Equinox included Bruce FeuchterJeff Estes and Matthew Brodsky. Tom Pascoe provided valuable assistance.